Table 3.
Determinants of severe morbidity among the 332 HIV-infected children on ART, followed-up at the CePReF between 2004–2009. Abidjan. Côte d’Ivoire. Joint Frailty adjusted model with estimated adjusted hazard ratios (aHR) and 95%CI
| aHR | IC95% | p | |
|---|---|---|---|
| For recurrences (severe morbidity) | |||
| Age at ART initiation | 0,793 | ||
| < 5 years | 1 | – | |
| ≥ 5 years | 1,04 | [0,77 – 1,41] | |
| Cotrimoxazole | 0,36 | [0,23 – 0,56] | <0,001 |
| CD4 % | <0,001 | ||
| < 15% | 1 | – | |
| 15 – 25 % | 1,57 | [1,13 – 2,18] | |
| ≥ 25% | 2,53 | [1,81 – 3,55] | |
| Gender: Male/Female | 1,04 | [0,79 – 1,37] | 0,947 |
| ART regimen | <0,001 | ||
| NNRTI | 1 | – | |
| PI | 1,83 | [1,35 – 2,47] | |
| Second line treatment | 0,68 | [0,42 – 1,12] | 0,127 |
| For survival | |||
| Age at ART initiation | 0,626 | ||
| < 5 years | 1 | – | |
| ≥ 5 years | 0,85 | [0,45 – 1,61] | |
| Cotrimoxazole | 2,52 | [0,81 – 7,87] | 0,111 |
| CD4 % | |||
| < 15% | 1 | – | <0,001 |
| 15 – 25 % | 2,11 | [0,76 – 5,87] | |
| ≥ 25% | 8,30 | [3,18 – 21,65] | |
| Variance of random effect, (SE) | 0,77 (0,11) | < 0,001 | |
| α* (SE) | 1,13 (0,33) | < 0,001 |
*
When α = 1, the effect of the frailty is identical for the recurrent events and the terminating event. When α > 1, the recurrent rate and the survival rate are positively associated.